Intelligent Oncology
Predicting cancer treatment response before therapy begins
Recent Releases
-
![]()
CHOSA Reports Positive Clinical Study Results for Platin-DRP® in Lung Cancer
In collaboration with ETOP and EORTC, platinum predictor demonstrates significant correlation with survival outcomes in NSCLC (30 Sept 2025)
-
![]()
CHOSA placed on the podium at at Jiangning 2025
CHOSA finishes in the top 3 at Jiangning 2025 International Entrepreneurship Contest in Nanjing, meeting investors and partners in China’s dynamic innovation hub late this September (Photo by Ling Tang)
-
![]()
CHOSA to Present Platin-DRP® Data in Breast Cancer at ESMO
New breast cancer findings support the gene signature’s ability to predict response to carboplatin treatment (08 August 2025).
-
![]()
CHOSA Oncology Presented at Aktiedagarna Stockholm
The presentaiton included it approach to precision medicine highlighting CHOSA's innovative strategies and upcoming milestones.
-
![]()
Interim Report Q2 now available
Published on 28 August 2025, the report details financial results, strategic progress, and milestones achieved in the second quarter.
We provide a safe and more effective solution for patients in need of platin-treatment
Platin-DRP®
Our patented Platin-DRP® analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most - at the tumor site - providing safer and more effective cancer care.
Key Opinion Leaders
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our Platin-DRP® and advances our mission toward precision oncology.
Dr. Fred Hirsch